News
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.
FEATURED STORIES
Last month, the FDA launched TrialBlazer, intended to streamline the IND path and bring early clinical trials and medical innovation home to the U.S. It’s a start, but new agency leadership must see it through.
Significant leadership instability at the FDA—compounded by continued workforce attrition—led to a slight slowdown in overall regulatory productivity in the first half of this year, but the agency has been catching up of late.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
If cell and gene therapy makers are going to achieve their mission to improve patients’ lives, the industry must come together to share information across stakeholders, from regulators to manufacturers to payers.
THE LATEST
Genentech’s flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.
New research from the Allen Institute for Immunology in Seattle has identified inflammatory proteins as a potential driver of the long COVID.
The rejection appears to be related to pre-approval inspection issues that need to be resolved before it can be approved.
Since the COVID-19 pandemic, there has been increased interest in developing a universal antiviral that would stop a pandemic in its tracks. Now some companies are in the testing phase for just that.
Marinus shared positive news in its financial report for the first quarter, led by updates from its Phase III trial on a drug for RSE and research efforts for rare diseases.
If you’re ready to start earning the salary you deserve, here are some tips to help you recognize your worth and negotiate pay as a remote employee.
Life sciences and biopharma companies strengthen their leadership teams and boards with these Movers & Shakers.
A group of scientists from the Babraham Institute in the United Kingdom has successfully rejuvenated skin cells by 30 years, observing several benefits of the functionally younger cells.
On Thursday at the White House, President Biden paid tribute to the 1 million American lives lost due to COVID-19.
CRISPR reported that the overall response rate (ORR) was 71% with 29% of patients experiencing a complete response. The data will be presented at EHA 2022.